

**REMARKS**

In response to the Restriction Requirement, applicants elect Group I (Claims 1-37 and 46-48 as denoted by SEQ ID NO. 1. Also regarding the indication, applicants elect (a) hematological disorders and myeloproliferative disorders (h).

With respect to the requirement to elect as species an indication, this election is made with traverse for the following reasons. It is respectfully submitted that all the indications result in an alteration of peripheral blood cells and that the decrease in peripheral blood cells has been resolved by the invention with the administration of OGP(10-14) and related pharmaceutical compositions. It has been shown by the invention that these compositions lead to mobilization of stem cells to peripheral blood. Therefore, all of the pathologies, particularly those grouped under the "hematological disease" species (i.e. the conditions e-h), are connected by a single inventive concept. For these reasons, withdrawal of the restriction with respect to species is respectfully requested.

Early and favorable action on the application is respectfully solicited.

Respectfully submitted,

Date: 9/29/06

A. Hobbs  
Ann S. Hobbs, Ph.D.  
Registration No. 36,830  
VENABLE  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 344-4000  
Telefax: (202) 344-8300  
[ashobbs@venable.com](mailto:ashobbs@venable.com)